#AS­CO2022 roundup: CG On­col­o­gy builds on head-turn­ing com­bo da­ta; EQRx doesn’t have a way in­to US mar­kets

CG On­col­o­gy at­tract­ed some at­ten­tion last month at #AACR22 for its ear­ly da­ta on its on­colyt­ic virus paired with Mer­ck’s Keytru­da for blad­der can­cer, and up­dat­ed num­bers from AS­CO don’t dis­ap­point.

In a Phase II study, 22 out of 24 pa­tients have had a com­plete re­sponse to the com­bo treat­ment at an ear­ly 3-month check-in, good for a 92% ini­tial re­sponse rate. At 6 months, that drops to 14 of 16, and at one year — the pri­ma­ry end­point of the study — 6 of 8 pa­tients main­tained a com­plete re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER